Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease

MedXY Editorial Team•Oct 6, 2026•Hematology-Oncology

Zilovertamab, a humanized monoclonal antibody against ROR1, was combined with the BTK inhibitor ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), demonstrating a favorable safety profile without dose-limiting toxicities.
The combination effectively suppressed key pro-survival signaling cascades including NF-κB, ERK1/2, and mTORC1, confirming mechanistic inhibition of ROR1-mediated pathways.
A post hoc analysis suggested that patients with the high-risk del(17p) cytogenetic abnormality experienced prolonged disease control compared to historical BTK inhibitor monotherapy data, highlighting a potentially important therapeutic avenue.
The findings support further prospective evaluation of ROR1-targeted strategies combined with BTK inhibition in biologically high-risk CLL subgroups.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Zilovertamab, a humanized monoclonal antibody against ROR1, was combined with the BTK inhibitor ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), demonstrating a favorable safety profile without dose-limiting toxicities.
The combination effectively suppressed key pro-survival signaling cascades including NF-κB, ERK1/2, and mTORC1, confirming mechanistic inhibition of ROR1-mediated pathways.
A post hoc analysis suggested that patients with the high-risk del(17p) cytogenetic abnormality experienced prolonged disease control compared to historical BTK inhibitor monotherapy data, highlighting a potentially important therapeutic avenue.
The findings support further prospective evaluation of ROR1-targeted strategies combined with BTK inhibition in biologically high-risk CLL subgroups.